The novel understanding that the presence of multiple islet autoantibodies, indicating islet autoimmunity, inevitably leads to type 1 diabetes mellitus (T1DM) has necessitated the development of a new staging classification system for the condition. Coupled with an improved understanding of the disease course, the realization that T1DM appears to be more heterogeneous than previously thought has led to unique opportunities to develop more targeted therapies that may be applied even before the onset of dysglycemia or symptoms. To date, several therapies have been trialed to delay or halt disease progression in both presymptomatic and clinical T1DM, each demonstrating varying degrees of effectiveness, toxicity, and utility. Key research supports the eventual implementation of immunotherapy in autoimmune diabetes, potentially calling for a paradigm shift among care providers. It will likely be necessary to develop new approaches to trial design and to address potential barriers to progress before an effective treatment for the disease may be achieved.
Type 1 diabetes mellitus (T1DM) may be diagnosed based on the recognition of at least two islet autoantibodies, denoting islet autoimmunity, before the development of dysglycemia or symptoms. Early detection grants the opportunity for early intervention. T1DM is a heterogeneous disease, greatly influenced by age at diagnosis and other factors. New and potentially even individualized approaches to therapy, possibly including combination therapies, may be necessary before a cure can be achieved.
Introduction
Almost 100 years after Dr. Frederick Banting and Dr. Charles Best's landmark discovery of insulin, the diabetes community can now boast multiple types and brands of insulins, many different insulin delivery devices, and hightech blood glucose monitoring systems. With the recent advent of the artificial pancreas, patients have renewed hope for better diabetes management options and improved glycemic control. However, whereas such advances have undoubtedly benefited those living with diabetes, they have served no role in actually preventing or altering the pathophysiology of the disease. It is generally accepted that the ultimate goal in the treatment of diabetes entails the prevention or deceleration of the autoimmune process behind beta-cell destruction.
In most other autoimmune conditions, immunotherapy is used as a means of preventing disease progression or decreasing disease severity. Such is the case with juvenile idiopathic arthritis (JIA). Before the acceptance of the use of immunotherapies in JIA, the goal of treatment was simply to control symptoms of the condition, such as joint pain and limited mobility. In the past few decades, immunotherapy has become more widely accepted and is now routinely prescribed to patients with JIA not only to treat but also to prevent joint erosion and disability. The use of such disease-modifying therapies has led to considerable improvements in quality of life for these patients [1] .
JIA has a similar prevalence to type 1 diabetes mellitus (T1DM), a similarly high clinical impact, a comparable long preclinical phase, and a parallel etiopathology in that both autoimmune diseases are considered to be polygenetic with unknown etiologic agents [2] . However, immunotherapy is not typically considered in T1DM.
Instead, for almost a century, the primary focus of treatment in T1DM has been on correcting hyperglycemia and preventing its associated consequences. Research on glycemic control, diabetes complications, and quality of life reveals that we have much to gain through the development of novel therapies. Studies such as the DCCT (Diabetes Control and Complications Trial) and follow-up EDIC (Epidemiology of Diabetes Interventions and Complications) trial have shown that poor glycemic control predisposes those with T1DM to retinopathy, neuropathy, nephropathy, cardiovascular disease, and other sequelae [3, 4] . Unfortunately, fewer than 30% of those with T1DM are currently meeting glycated hemoglobin (HbA 1c ) goals, and mortality rates among patients with T1DM remain significantly higher than those for the general population [5, 6] .
A proactive treatment approach, aimed at preventing or slowing beta-cell destruction, and consequently curbing dysglycemia and its associated complications, has the potential to improve quality of life and decrease the overwhelming disease burden of T1DM. While we do not yet have therapies approved for clinical use, much progress has been made in recent years toward better understanding the T1DM disease course, and several therapies have already been shown to curtail beta-cell destruction, at least temporarily. Many therapies have demonstrated differences in efficacy among unique subject populations, suggesting that the disease may be more heterogeneous than previously thought. Such advances in our understanding of T1DM will allow for greater opportunity to develop more targeted therapies. Accordingly, it is not unreasonable to imagine the use of disease-modifying therapies for T1DM in the not-too-distant future.
New Insights into the Disease Course
In 1986, Dr. George Eisenbarth proposed that T1DM was likely characterized by an unidentified precipitating event followed by a linear decline in beta-cell function, eventually leading to a complete absence of insulin secretion [7] . However, in the last decade, natural history studies have revealed that beta-cell decline is not necessarily linear and may not be absolute. Recent data demonstrate that beta-cell dysfunction in autoantibody-positive individuals is accelerated in the 6-12 months before clinical onset. Data from new-onset studies suggest that the decline in insulin secretion is also accelerated in the period shortly following the development of symptomatic disease. This pronounced loss of beta-cell function persists for approximately 1 year following clinical diagnosis, after which insulin secretion continues to diminish but at a decelerated rate [8, 9] . An improved understanding of the clinical course of T1DM has implications for the development and administration of therapies, as it can be assumed that efforts to preserve beta-cell reserve and function would have the greatest hope of efficacy if applied before periods of rapid beta-cell functional loss [10] .
It has also been recently recognized that not all individuals experience an inevitable absence of insulin secretion. Results from the Joslin Medalist Study, multiple autopsy studies, and organ donor tissue studies show evidence of functional beta-cells in those with longstanding T1DM [11] [12] [13] . In the Medalist Study, 67.4% of participants with a diabetes duration ≥ 50 years had random serum C-peptide levels in the minimal (≥ 0.03 nmol/l) or sustained (≥ 0.20 nmol/l) range, and postmortem analysis of pancreata from nine medalists revealed insulin-positive betacells in all participants. Unsurprisingly, individuals with shorter diabetes duration were more likely to exhibit high levels of C-peptide production. Type 1 Diabetes TrialNet, an international clinical trials network funded by the National Institutes of Health (NIH) and aimed at developing diseasemodifying therapies, has been following individuals with preclinical, new-onset, and longstanding diabetes for almost 2 decades. Combined data from multiple TrialNet studies show that 88% (at 12 months post-diagnosis) and 66% (at 24 months post-diagnosis) of those with new-onset T1DM have peak C-peptide ≥ 0.20 nmol/l on mixed meal tolerance test (MMTT) [30] . As discussed below, this is the amount of C-peptide thought to be necessary for clinical benefit. Data from the T1DM Exchange Clinic Network demonstrate that almost one in three individuals with a diabetes duration of 36 months to more than 40 years has measureable residual insulin secretion, although the amount of secretion is almost always very low and rarely approaches clinically important levels [14] .
Given the evidence of insulin production in those with longstanding T1DM, one might conclude that those with the disease could benefit from therapies aimed at beta-cell preservation or restoration, even several years or decades after diagnosis. However, it is important to note that, whereas C-peptide may be detectable in an individual, the level or duration of C-peptide production that would confer clinical benefits remains unclear. Post hoc analysis of data from the DCCT showed that a peak C-peptide of ≥ 0.20 nmol/l was associated with a decreased likelihood of progression to retinopathy or severe hypoglycemia [15] . Among the Medalist cohort, only 2.6% of individuals had this level of C-peptide upon MMTT. Interestingly, further analysis from the DCCT suggests that any detectable C-peptide is better than none and may correlate with a decreased risk of diabetes complications [16] . Similar observations have been made in islet transplant studies, where C-peptide levels insufficient to render participants insulin independent are effective in decreasing hypoglycemic unawareness [17, 18] .
Starting Point: Genetic Risk
Family and twin studies reveal that genetics certainly play an important role in the development of T1DM. In the past couple of decades, researchers have recognized that, whereas the risk of T1DM for people in the general population is approximately 1/300, those with a first-or second-degree relative with T1DM have a risk of 1/20. Stated another way, relatives have a 15 times increased risk of disease over that of the general population [19] . Among monozygotic twins, the risk is even higher, with disease concordance approaching 40% across age groups. This risk appears to be even higher when the index twin is diagnosed in early childhood [20] .
The strongest association between genes and disease, accounting for up to 60% of genetic risk, is seen within the human leukocyte antigen (HLA) region on chromosome 6 [21] . Specifically, the HLA class II DR3/DR4 genotype is known to confer the greatest risk for disease among Caucasian populations, being found in about 95% of those with T1DM and only 60% of those without disease [21] [22] [23] . In contrast, HLA class II DQB1*0602 is associated with protection from disease; it is present in > 20% of the general Caucasian population and in < 1% of children who develop T1DM [24] . It is important to note that the HLA genotypes most commonly associated with T1DM vary among different ethnic populations. For example, the DR3/DR4 genotypes that are so prevalent among Caucasians with T1DM are actually very unusual in Japanese populations. Among Japanese, the DR4-DQ (DRB1*0405-DQB1*0401) and DR9 (DRB1*0901-DQB1*0303) HLA haplotypes, which are rare in Europeans, are most commonly associated with disease susceptibility [25, 26] . It is also worth mentioning that the positive predictive value of genotype is low, as only about 5% of those with even the highest-risk HLA types ever advance to symptomatic T1DM [27] [28] [29] [30] . Understanding of this fact has led to an increased interest in screening family members of those with T1DM for alternate disease markers such as diabetes autoantibodies (see Sect. 4) and in preventing the development and progression of disease in this higher-risk population [31] .
The linkage of T1DM with the HLA class II region highlights the importance of adaptive immunity in disease, as these genes make proteins responsible for antigen recognition and CD-4 T-cell activation [25] . T1DM predisposition can further be attributed to roughly 50 other non-HLA genes or loci, including the INS, PTPN22, CTLA4, and IL2RA genes, all of which have been shown to have small to moderate effects on disease risk through a variety of mechanisms [32] . Again highlighting the importance of the immune system in T1DM, in contrast to the genes that predispose to type 2 diabetes mellitus (T2DM), few of these genes are thought to be related to beta-cell function or metabolism.
Genetic studies have also provided clues to understanding the initiation and progression of disease. The TEDDY (Environmental Determinants of Diabetes in the Young) study, which follows genetically at-risk infants and children, initially found that autoantibodies to insulin generally developed before autoantibodies to GAD65. However, further analysis revealed that the order of appearance of autoantibodies was related to HLA-DQ genotype. Children with HLA-DQ2/8, DQ8/8, and DQ4/8 primarily developed insulin autoantibodies first, whereas children with DQ2/2 initially developed GAD65 autoantibodies. The TEDDY study also found that early autoantibody seroconversion was more commonly seen in children with the high-risk HLA DR3/4-DQ8 or DR4/4-DQ8/8 genotype. These findings suggest there may be distinct etiopathologies of T1DM related to HLA type [33, 34] . While HLA class II genotype impacts the development of autoantibodies, it does not appear to influence the course of disease after the onset of islet autoimmunity [24] . Conversely, several of the non-HLA T1DM susceptibility genes, including IL2, CD25, INSVNTR, IL18RAP, PTPN22, IL10, and others, have been shown to influence the rate of disease progression even beyond the development of autoantibodies [35] .
Diabetes Autoantibodies Instrumental in Identifying Disease
Given the low positive predictive value of genetic factors, the recognition of diabetes autoantibodies such as GAD65 (GADA), zinc transporter 8 (ZnT8A), insulin (IAA), islet cell antibodies (ICA), insulinoma-associated proteins (IA-2A and IA-2β), and others as markers of autoimmunity has been critical to the identification and definition of the preclinical stages of T1DM. To learn more about the significance of autoantibody positivity, TrialNet designed TN01, the Pathway to Prevention Study. TN01 has served to determine the prevalence and prognostic value of diabetes autoantibodies among first-and second-degree relatives of those with T1DM, who, as previously noted, are at increased genetic risk for disease [31] . TrialNet currently offers free autoantibody screening to first-degree relatives aged 1-45 years and second-degree relatives aged 1-20 years.
To date, more than 200,000 individuals have been screened for autoantibodies through TN01, with ~ 15,000 new relatives tested annually. Approximately 5% of those screened through this program are found to be autoantibody positive [19] . Results from this study and similar prospective studies have shed much light on the natural history of the disease [34, 36, 37] . We now understand that 95% of individuals destined to progress to symptomatic T1DM before puberty will be autoantibody positive by the age of 5 years [38] . In the TEDDY study, the initial detection of autoantibodies peaked between 9 and 24 months of age [39] . Available data also suggest that an individual who demonstrates positivity for at least two autoantibodies, denoting islet autoimmunity, will eventually progress to clinical T1DM. While several factors, including age and autoantibody profile (see Sect. 6) do affect the rate of progression to symptomatic T1DM, multiple autoantibody positivity has been repeatedly shown to be highly predictive of disease across all phenotypes [31, 40] . Among genetically at-risk children followed from birth who progress to multiple autoantibody positivity, the 10-year risk of symptomatic T1DM is 70%, and the lifetime risk approaches 100% [36] . Predictably, once an individual displays not only multiple autoantibody positivity but also abnormal glucose tolerance, risk of progression to symptomatic T1DM is even higher, with 60-75% of those who fall into this category reaching clinical diagnosis within only 5 years. Again, lifetime risk of disease among this population approaches 100% [31, 41] . The prognostic value of single autoantibody positivity is less clear, although it does appear that the presence of a single autoantibody confers significantly more risk of progression to T1DM in children than in adults (see Sect. 6) [40] .
Some research has shown that the risk conferred by multiple autoantibody positivity is not limited to relatives of those with T1DM. For instance, a study recently reported that the risk of progression to symptomatic T1DM from the time of seroconversion to multiple autoantibody positivity was nearly 84% within 15 years among three pediatric cohorts from Finland, the USA, and Germany [36] . Notably, whereas the German and US participants did include relatives of T1DM probands, the Finnish participants were recruited from the general population based on high-risk HLA genotype. Even though two cohorts included T1DM family members and one did not, rates of progression to T1DM from recognized islet autoimmunity were the same in all three cohorts. This suggests that, once autoantibodies are detectable, disease advances in a similar manner regardless of family history. The TEDDY study recruits both neonates from the general population based on high-risk HLA type and neonates with family members with T1DM and then follows participants every 3-6 months until the age of 15 years for the development of autoantibodies. This study confirms these findings, again showing that once multiple autoantibodies appear, the risk of progression to clinical T1DM is consistent among all participants [42] . With this new information, TrialNet is now opening its diabetes intervention studies to all individuals with multiple autoantibody positivity, regardless of family history.
Depending on autoantibody screening results, participants in trials such as TN01 may be offered additional annual or semi-annual monitoring of their autoantibodies and glycemic status or the opportunity to enroll in one of several clinical trials aimed at slowing disease progression (see Sect. 7). A growing body of evidence suggests that individuals at high risk of disease development who are closely monitored for progression are considerably less likely to experience peridiagnostic diabetic ketoacidosis (DKA) and exhibit lower HbA 1c levels at diagnosis than those diagnosed in the community via symptom recognition ( Fig. 1 ) [43] [44] [45] . In the DPT-1 (Diabetes Prevention Trial-Type 1), where high-risk family members underwent semi-annual oral glucose tolerance tests (OGTTs) to follow disease progression, only ~ 4% of individuals with newonset T1DM presented with DKA [7] . In contrast, 20-40% of patients with new-onset T1DM present with DKA when diagnosed in the community without the benefit of monitoring programs [46] . Even a slight reduction in incidence of this common and potentially fatal condition is significant. In light of such benefits, the American Diabetes Association (ADA) has recommended since 2009 that family members of individuals with T1DM be made aware of the opportunity to screen for autoantibodies in the context of a clinical research trial such as TN01 (see https ://trial net.org/) [47] .
Given the high disease risk identified by multiple autoantibody positivity and the benefits of monitoring high-risk individuals for disease progression, some have posited that screening the general population for autoantibodies is warranted [52] . To date, population-wide screening has only been done in the context of clinical research trials [53, 54] . For instance, the Fr1da study aims to screen 100,000 children aged 2-5 years throughout Bavaria for autoantibodies at routine health examinations performed by their pediatricians. So far, preliminary results show that multiple autoantibodies have been detected in 4 of every 1000 individuals tested. Those who screen positive for autoantibodies are offered additional diabetes education through the study [53] . While screening for autoantibodies is readily feasible, the reduction in HbA 1c and DKA at time of clinical diagnosis previously noted was the result of regular monitoring, not just screening. Given the low overall incidence of T1DM (< 0.5% in the general population), the possibility for false-positive results, and the present lack of clinical guidelines concerning what actions should be taken when a positive autoantibody test result is obtained, many financial and logistical barriers must be addressed before population-wide screening is adopted as part of clinical practice [55, 56] . Yet, as soon as a successful disease-modifying therapy is available, routine screening of the general population will be essential to impact disease incidence; whereas risk remains greatest in relatives, 85% of those who develop T1DM have no family history [57] . To prepare for this, multiple approaches to population-wide screening are being tested [58, 59] .
New Staging Classification System for Type 1 Diabetes Mellitus (T1DM)
In response to the increased understanding of the path to T1DM, in October 2015, JDRF, the Endocrine Society, and the ADA released a scientific statement endorsing the adoption of an official staging classification system for the disease ( Fig. 2 ) [33] . According to this new system, T1DM can now be categorized into three distinct stages. Before stage 1 disease, it is believed that an as-yet unidentified inciting event activates the immune system against the beta-cells, triggering the production of autoantibodies. [60] . Finally, stage 3 denotes the onset of clinical T1DM, which is usually but not always accompanied by symptoms such as polyuria, polydipsia, weight loss, and DKA, among others. This staging system introduces the concept that T1DM starts at the time of multiple autoantibody development. Thus, clinical trials designed for those in stage 1 and stage 2 T1DM can now be considered to treat rather than prevent early disease.
Factors Known to Influence Rate of Progression through Stages of T1DM

Age
Multiple factors are known to influence the disease course of T1DM, offering the possibility of predicting how rapidly an individual will advance from autoantibody positivity to stage 3 T1DM and on to loss of clinically significant insulin secretion. A person's age has one of the most significant influences over disease progression, with younger individuals moving more rapidly through all three stages of T1DM.
To illustrate, children with a single autoantibody are more likely to progress to multiple autoantibody positivity than adults [31, 34] . A recent analysis of TrialNet data showed that single autoantibody-positive children aged < 8 years had a 35-37% risk of progression to multiple autoantibody positivity within 5 years, whereas adults aged > 18 years had a 13-16% chance of progression [40] . Further research has
shown that young children typically convert from single to multiple antibody positivity within 2 years, with progression less frequent after 4 years of initial seroconversion. Immune responses in adults have been shown to mature over a longer period of time [62, 63] . Similarly, once islet autoimmunity is established, children are more likely to advance to dysglycemia (stage 2 T1DM) and from dysglycemia to symptomatic (stage 3) T1DM than are adults [31] . Interestingly, risk of progression has also been shown to be increased among individuals whose T1DM proband was diagnosed at a younger age, once again highlighting the heterogeneous nature of the disease [64] . Age continues to be impactful even after diagnosis, as decline in C-peptide is significantly more drastic over the first 2 years post-diagnosis in individuals aged ≤ 21 years than in those aged > 21 years [9] . The effect of age at diagnosis upon residual insulin secretion can also be seen in those with longstanding T1DM. Whereas only 20% of children diagnosed when aged ≤ 18 years will have any detectable C-peptide 6-9 years after diagnosis, 60% of adults with an equivalent diabetes duration will demonstrate insulin production [14] . The more pronounced beta-cell loss seen among children with T1DM could signify a more aggressive disease course or may be attributed to the fact that young children may have fewer beta-cells at diagnosis than their adult counterparts. 
Autoantibody Profile
T1DM risk appears to vary with autoantibody number, titer, specificity, and type, as demonstrated by multiple longitudinal studies, including TEDDY, DPT-1, and TN01 [19, 31, 37, 40, 65] . In DPT-1, risk of progression to symptomatic T1DM intensified with increasing number of autoantibodies. Relatives of probands with T1DM across all age groups had a 25% chance of progression to stage 3 T1DM over 5 years if positive for two autoantibodies, a 40% chance if positive for three autoantibodies, and a 50% chance if positive for four autoantibodies [37] . Subsequent data from the TrialNet group confirm these trends. Those with higher autoantibody titers have also been noted to have a greater risk of progression to stage 3 T1DM [66, 67] . However, as autoantibody titer is highly correlated with autoantibody number, the utility of this marker is confounded [60] . Recently, an analysis of data from the TrialNet Pathway to Prevention Study showed that the pattern of progression to T1DM may also vary by autoantibody type. Single autoantibody-positive relatives with IAA were most likely to develop additional autoantibodies in early childhood, but the risk of progression decreased dramatically after the age of 8 years. In contrast, individuals with high GAD antibody titers maintained a high risk of progression to multiple autoantibody positivity even after early childhood [40] . This and other data support the idea that T1DM may have multiple possible etiologies and pathways.
Immunotherapy for T1DM
Since the first description of T1DM as an autoimmune disease over 30 years ago [7] , investigators have used immunotherapy to intervene in the natural course of T1DM. This approach has been validated by the evidence that stage 1 T1DM can be identified early with diabetes-specific autoantibodies. As with any therapy, immunotherapy must balance the risks and burdens of treatment with the potential benefits. The earliest immunotherapies tested in T1DM were broad in their targets and often too toxic for widespread clinical use.
One of the earliest immune agents used was cyclosporine, a non-specific immunosuppressant. Although 1 year of treatment with cyclosporine produced insulin independence in a majority of children with new-onset (stage 3) T1DM, remission required chronic therapy, and chronic therapy led to nephrotoxicity [68] . Since the cyclosporine and other first-generation immunotherapy studies, available immunotherapies have become safer and more targeted. Simultaneous with improvements in therapies, disease mechanisms and specific immune targets have been identified in T1DM. The following section highlights some general approaches towards immunotherapy in T1DM, and Fig. 3 illustrates some of these approaches.
Targeting Inflammation with Specific Anti-Inflammatory Agents
Beta-cell inflammation may be a necessary component of beta-cell death in T1DM. As such, both specific and more general anti-inflammatories have been tested, mostly in stage 3 (new-onset) disease.
Interleukin (IL)-1
Interleukin (IL)-1 is a cytokine important in the normal response to infection and inflammation. IL-1 blockade has been effective for treatment of rheumatoid arthritis and juvenile rheumatoid arthritis and is being tested for treatment of more general inflammatory conditions, particularly atherosclerosis [70] . Two different IL-1 blocking agents (anakinra and canakinumab) have been tested in phase II studies in stage 3 T1DM but failed to show any significant C-peptide preservation in treated individuals [71] .
Tumor Necrosis Factor (TNF)-α
A 2009 pilot study (n = 18) in children with stage 3 disease using the tumor necrosis factor (TNF)-α inhibitor etanercept demonstrated an increase in C-peptide level and lower HbA 1c in treated individuals [72] . Golimumab, also a TNF-α blocker, is currently in clinical trial in children with stage 2 [73] and stage 3 T1DM [74] .
Il-12/23
The IL-12/23 cytokine pathway is an attractive therapeutic target because of its involvement in multiple immune pathways, including the release of proinflammatory cytokines and the support of pathogenic T-effector (Teff) cells. The IL-12/23 blocking agent ustekinumab has been approved for use in psoriasis, psoriatic arthritis, and Crohn's disease.
USTID (Pilot Clinical Trial of Ustekinumab in Patients With
New-onset T1DM) is a small (n = 20) JDRF-sponsored phase I/II Canadian study testing ustekinumab in adults with stage 3 T1DM [75] . USTID has completed enrollment.
Il-6
IL-6 is a compelling target of autoimmunity because of its effects on both innate and adaptive immunity. In T1DM, it promotes pathogenic Teff T-helper (Th)-17 cells; furthermore, a subset of people with T1DM have been shown to have an exaggerated response to IL-6 [76] . Anti-IL-6 therapies are currently used to treat rheumatoid arthritis, JIA, and temporal arteritis. The EXTEND study [77] , conducted by the Immune Tolerance Network (ITN), has completed enrollment of both adults and children with stage 3 T1DM and is testing whether 6 months of treatment with the IL-6 receptor blocker tocilizumab can preserve beta-cell function.
Targeting Inflammation with General Anti-Inflammatory Agents
Alpha-1 Antitrypsin
Alpha-1 antitrypsin (A1AT) is a serum protease inhibitor that suppresses pro-inflammatory cytokines, including TNF-α, IL-1, and IL-6. A1AT levels are normal in T1DM, but reports have described impaired activity [78] . Early small studies in children and adults have demonstrated that A1AT is safe and well-tolerated in stage 3 T1DM [79] . Other studies are testing the effects of A1AT in more established disease [80, 81] .
Tyrosine Kinase Inhibition
Imatinib, a tyrosine kinase inhibitor, has broader anti-inflammatory effects and may play a role in T1DM. Imatinib is known mostly for its efficacy in chronic myelogenous leukemia and other malignancies. In the non-obese diabetic (NOD) mouse, imatinib can reverse diabetes [82] , a finding that prompted a human trial, Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus [83] . The preliminary 1-year results of this study in adults with stage 3 T1DM were released in June 2017 at the ADA Scientific Session [84] ; further trials in children using imatinib are being considered.
Targeting Antigen Presentation
Antigen presentation is the multistep process by which proteins are presented to the immune system and then elicit an immune response, either tolerance or activation. Autoimmunity might be a failure of this process. Different strategies have been proposed and tested to redirect the immune response towards tolerance or away from auto-reactivity, some of which are highlighted in the following subsections.
Antigen Therapy
Repeated early exposure of an antigen to the naïve immune system may facilitate immune tolerance to that antigen. This approach has been successful in peanut allergies, where, in genetically at-risk children, earlier exposure to peanut protein has been shown to decrease rates of future clinical peanut allergy [85] . Antigen therapy has been tested in both islet autoimmunity (stage 1) and in new-onset (stage 3) T1DM. As described, insulin and GAD65 antibodies mark the presence of an immune response directed at these selfproteins. Studies in stage 1 T1DM have investigated whether repeated exposure to insulin (orally, nasally, or parenterally) can prevent or delay stage 3 T1DM. GAD65 therapy has been tested in both stage 1 and stage 3 T1DM. While antigen therapy (with insulin or GAD65) appears to be safe and welltolerated, none of these approaches has been effective. Notably, trials testing oral insulin in primary prevention, before 
Target Antigen-Presenting Cells
Another strategy is to interfere with specific antigen-presenting cells such as the B cell. This has been tested with the B-cell-depleting agent rituximab, which can delay loss of C-peptide in stage 3 disease. Pescovitz et al. [86] found that four weekly infusions of rituximab preserved C-peptide by 8.2 months compared with placebo. Rituximab has not been tested in earlier-stage disease; but targeting B cells remains attractive, and additional trials are planned.
Block Major Histocompatibility Complex Function
Proteins and peptides are presented to the immune system in a major histocompatibility complex (MHC)-dependent process. Interestingly, antigen presentation can be blocked mechanically with a small molecule, methyldopa, an alphaadrenergic blocker approved by the US FDA and used for decades to treat hypertension and pregnancy-induced hypertension. Methylodpa interferes directly with antigen presentation in individuals with DQ8 MHC class II alleles. DQ8 is present in 50-60% of people with T1DM and of those at risk. Preclinical studies [87] and a phase Ib escalation study [88] suggest that methyldopa can safely and durably block antigen presentation in this fashion. TrialNet aims to launch a study to evaluate the ability of methyldopa to block ongoing immune destruction of beta cells in relatives at risk of T1DM [89] .
Targeting T Cells
Another target of immunotherapy in T1DM is the T cell.
Multiple agents that interfere with T-cell activation, reduce the number or function of pathogenic Teff cells, or increase the number or function of T-regulatory (Treg) cells have been tested.
T-Cell Signaling
Abatacept, a CTLA4 immunoglobulin, is currently used to treat rheumatoid arthritis, JIA, and psoriatic arthritis. It blocks the costimulatory signal necessary for activation of naïve T cells, hence rendering the T cell anergic. Abatacept has demonstrated efficacy in stage 3 disease, where monthly infusions for 2 years delayed C-peptide decline by 9.6 months [90] . In follow-up to the promising results in stage 3 disease, TrialNet is enrolling a study to test whether abatacept given earlier, in stage 1 T1DM, can delay the onset of stage 2 or stage 3 T1DM [91].
Anti-CD3 Therapy
The anti-CD3 monoclonal antibody binds to the CD3/T-cell receptor (TCR) complex, which leads to disappearance of the CD3/TCR complex and renders the T cell anergic to its target antigen. A number of studies have tested anti-CD3 agents, including teplizumab and otelixizumab, both of which have demonstrated efficacy in stage 3 T1DM. Herold et al. [92] tested a single 14-day course of teplizumab and demonstrated a delay in loss of C-peptide in teplizumabtreated compared with placebo-treated groups. In the AbATE trial, a second 14-day teplizumab course was given 1 year after the first course, resulting in C-peptide preservation, with an average 15.9 month delay in loss of C-peptide at 2 years [93] . These promising results supported a study looking at earlier-stage disease. In 2010, TrialNet initiated a study investigating whether a single 14-day course of teplizumab in individuals with stage 2 T1DM could delay or prevent the onset of stage 3 T1DM [94] . Results of this study are expected in 2019.
Anti-CD2 Therapy
It is possible that, despite the elimination of a significant portion of Teff cells, destruction of memory Teff cells would also be required to create lasting effects. This has been tested with alefacept, an anti-CD2 fusion protein that blocks T-cell activation and induces apoptosis of memory Teff lymphocytes. TIDAL, an ITN study for which results were published in 2015, enrolled 49 children and adults aged 12-35 years with stage 3 T1DM. Participants were treated with two 12-week courses of drug or placebo. Unfortunately, the study was not fully enrolled because of insufficient drug availability. Despite this limitation, a non-significant trend towards preservation of C-peptide, lower insulin usage, and fewer hypoglycemic events was seen at 1 year [95] . These metabolic benefits were sustained at 15 months beyond treatment [96] .
Anti-Thymocyte Globulin
Anti-thymocyte globulin (ATG) depletes activated T cells; in lower doses, it appears to deplete primarily Teff cells, and in higher doses it depletes both Teff and Treg cells. Lowdose ATG has been used in combination with granulocyte colony-stimulating factor (GCSF), which supports leukocyte recovery; in particular, GCSF favors recovery of Tregs. A pilot study (n = 24) published in 2015 in people with stage 3 T1DM (4 months-2 years after diagnosis) suggested the ATG/GCSF combination was safe and that a trend toward C-peptide preservation was seen [97] . A larger TrialNet study testing the combination of low-dose ATG and GCSF versus low-dose ATG alone versus placebo in stage 3 disease was completed in 2016. At 1 year after treatment, low-dose ATG alone significantly preserved C-peptide relative to the placebo group. Thus, this trial demonstrated that GCSF provided no additional benefit. The 2-year clinical and mechanistic results are expected in 2019 [98] .
Low Dose IL-2
Some individuals with T1DM have impaired responsiveness to IL-2, a cytokine with competing immune effects depending on dosage. IL-2 promotes Teff activity at higher doses and promotes Treg activity at lower doses. A pilot study in 2012 tested the combination of IL-2 with rapamycin, the latter of which blocks Teff cells. The combination was predicted to enhance the activity and survival of Tregs while reducing Teff effects. Although this immune benefit was seen, so were clinically important adverse effects, including a transient decrease in C-peptide [99] regardless of whether participants received the rapamycin. The study was terminated early, and mechanistic studies found that IL-2 stimulated both regulatory and natural killer cells. While studies testing whether a lower dose of IL-2 would boost Treg activity without the adverse effects seen in the pilot study are ongoing [100] , the narrow therapeutic window for beneficial effects compared with untoward effects with currently available IL-2 are challenging. Thus, variants of IL-2 that may convey more specificity for Treg cells are under development.
T-Regulatory-Cell Infusion
A more direct method of increasing Tregs is by infusion of ex vivo expanded autologous Tregs. A small (n = 14) phase I dose-finding study reported in 2015 demonstrated the safety and tolerability of Treg therapy in stage 3 T1DM [101] . A similar phase I study (n = 14) [102] recently completed enrollment. The TILT study (A Phase I Trial of CD4 + CD127lo/-CD25 + Polyclonal Treg Adoptive Immunotherapy with Interleukin-2 for the Treatment of Type 1 Diabetes) investigated whether autologous Treg therapy combined with low-dose IL-2 treatment immediately after Treg infusion and again 1 month after infusion could provide additional Treg support [103] . As reported at the Immunology of Diabetes Society (IDS) meeting in London, 2018, this approach also led to transient impairment in C-peptide.
Beta-Cell Support
Agents to support the beta cell are unlikely to alter the underlying immune defects in T1DM, but they may be useful in combination with immunotherapy. Multiple agents have been tested; namely, metformin, glucagon-like peptide (GLP)-1 agonists such as liraglutide, proton pump inhibitors (PPIs) such as omeprazole, and hydroxychloroquine.
Metformin
While metformin can allow for reduced insulin doses and appears to be safe in established T1DM, it does not offer any significant clinical benefit as measured by HbA 1c [104] . However, whether metformin might protect the beta cell or reduce beta-cell stress in earlier-stage T1DM is unknown. The adAPT (Accelerator Trial) is a randomized controlled trial [105] testing whether treatment with metformin in children with stage 1 T1DM can affect markers of beta-cell function and reduce the progression towards stage 3 T1DM.
Glucagon-Like Peptide-1 Agonists
In the presence of hyperglycemia, GLP-1 suppresses glucagon and stimulates insulin secretion [106] . Clinical benefits include improved glycemic control and weight loss without a risk of hypoglycemia [107] . Mouse studies have demonstrated that GLP-1 treatment can promote beta-cell proliferation and survival, reduce apoptosis, and delay autoimmune diabetes [108] . Furthermore, mouse studies have shown reversal of autoimmune diabetes when GLP-1 agonists are combined with immunotherapies. These effects have not been demonstrated in human disease. In fact, few human trials have tested beta-cell-specific outcomes with GLP-1 treatment. Unsurprisingly, GLP-1 treatment in patients with longstanding T1DM does not appear to alter C-peptide secretion [109] . However, GLP-1 agents might have a greater effect in earlier stages of disease when beta-cell mass is greatest. Ongoing studies are testing this idea in all stages of T1DM, including stage 3 with residual C-peptide [110] [111] [112] , stage 2 [113] , and stage 1 disease [114] .
Proton Pump Inhibition
PPIs are used clinically to treat gastroesophageal reflux disease and peptic ulcer disease. Among other effects, PPIs increase gastrin levels, which, in animal models, can boost beta-cell mass and therefore might be expected to have beneficial effects in human diabetes [115] . However, human studies on the effect of PPIs and glycemia have been mixed [116] [117] [118] .
Hydroxychloroquine
Hydroxychloroquine is FDA approved for treatment of malaria, lupus, and rheumatoid arthritis. Interestingly, it has been shown to improve insulin sensitivity and beta-cell function [119] . In 2018, TrialNet launched a trial to investigate whether hydroxychloroquine therapy can delay or prevent stage 2 or 3 T1DM in family members with stage 1 T1DM [120] .
Other Approaches to Disease-Modifying Therapy
Preclinical studies in autoimmune diabetes have suggested that short-term treatment with a variety of different immunotherapies could produce durable disease remission in animals. Based on successes in animal models of T1DM, this was the strategy employed in human clinical trials, that is, short-term therapy to delay the loss of C-peptide. In stage 3 (new-onset) T1DM, many short-term therapies have shown some efficacy and with a reasonable safety profile. However, the results were similar among these studies: beta-cell function was preserved for a period of time, after which C-peptide declined again. This observation is illustrated in Fig. 4 . Although these results consistently illustrate that immunotherapy can alter the natural course of T1DM, especially in children, no therapy has yet produced a durable remission, which suggests that other strategies may be needed to produce long-term C-peptide preservation. However, even short-term C-peptide preservation may have some benefits if it correlates with better glycemic control. The DCCT showed that intensive glycemic control for a mean of 6.5 years led to better clinical outcomes, even years after study completion, after which HbA 1c values in the two groups converged [121] [122] [123] . This sustained benefit to early glycemic control has been termed "metabolic memory," and it may be an additional benefit to short-term C-peptide preservation in stage 3 T1DM.
Combination Therapy
With the increasing understanding that T1DM pathogenesis may involve multiple immune defects and multiple steps, combination therapy may produce a more durable remission. However, combination therapy must be approached with caution, as it may expose participants to additional risk. Certain strategies may mitigate the additional risk, for example, using therapies with non-overlapping but complementary mechanisms. As described, the combination of low-dose ATG and GCSF would be expected to deplete T lymphocytes with relative sparing of Tregs, yet the clinical trial found no benefit with the GCSF. Several trials are being considered whereby therapy will be administered sequentially; the aim being to gain the benefits of combined approaches while limiting the potential for increased risks.
Chronic Therapy
Short-term immunotherapy in T1DM has not produced a durable remission but continues to be the approach to disease-modifying therapy. Contrast this with approaches in other autoimmune conditions (rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis), where the standard of care is early and ongoing or intermittent treatment with single or combination disease-modifying therapies to alter disease course by preventing tissue destruction and therefore also treating symptoms, including pain and loss of function. It is also understood that any single therapy may eventually lose efficacy, necessitating serial use of multiple therapies over the course of a lifetime. Chronic, sequential, or intermittent therapy has not been used in T1DM since the cyclosporine studies decades ago; but trials testing these approaches are being planned.
Earlier Therapy
It makes sense that we would intervene earlier in the disease course to preserve beta cells before T1DM becomes clinically apparent. Although we have evidence that beta cells can be preserved in stage 3 disease (after clinical diagnosis), at least for a period of time, less is known about the efficacy of immunotherapy in stage 1 or 2 disease or even earlier, before islet autoimmunity begins.
Selected Therapies to Prevent Stage 1 T1DM (Islet Autoimmunity)
Observational studies and demographic trends suggest multiple possible environmental triggers of islet autoimmunity. For example, T1DM and autoimmunity in general have increased with increasing westernization, a phenomenon that contributes to lower vitamin D levels, more hygienic standards of living, changing dietary patterns, etc. The number of randomized primary prevention trials in T1DM are limited, partly because of the complexity and expense involved in such human trials and because any intervention directed toward primary prevention must be both safe and tolerable. For decades, observational studies have suggested that breastfeeding is associated with decreased rates of T1DM, but there were no randomized trials to support this finding. TRIGR (Trial to Reduce IDDM in the Genetically At Risk) is a multicenter international study that randomized 2160 genetically at-risk infants to two feeding arms: either weaning to conventional cows' milk formula or weaning to hydrolyzed casein formula, in which proteins are hydrolyzed to be non-immunogenic. In both groups, exclusive breastfeeding was recommended until the age of 6 months. There was no benefit to weaning to hydrolyzed formula over conventional formula in the incidence of either islet autoimmunity [124] or stage 3 T1DM [125] . Similar to the idea that breastfeeding may be protective, observational studies have suggested that delayed introduction of dietary gluten may be protective [126] . However, this observation has not been supported by a randomized trial. BABYDIET is a German birth cohort study that randomized 150 genetically at-risk infants to two feeding arms: one arm introduced dietary gluten at the age of 6 months, which is the standard recommendation in Germany, and one arm delayed introduction of gluten until 12 months. Although it was safe to delay gluten exposure, no change was demonstrated in the incidence of islet autoimmunity with delayed introduction of dietary gluten [127] . 
Selected Previous Studies Testing Therapies to Delay
Antigen Therapies
Conceptually, antigen therapy might be expected to induce immune tolerance if introduced early and repeatedly to a maturing immune system. However, it is also possible that antigen treatment might "feed the fire" of an autoimmune response. Therefore, in T1DM, early studies of antigen therapy were performed in stage 3 T1DM, where clinical disease is already present. Candidate therapies were target antigens or peptides of the autoimmune response, including insulin, GAD65, and proinsulin peptide, which is a short immunogenic portion of the larger proinsulin molecule that, in animal models of autoimmune diabetes, induces a pro-regulatory immune response [129] . Although studies in stage 3 T1DM demonstrated safety of these therapies, perhaps unsurprisingly, they were mostly negative in their ability to preserve C-peptide [130] [131] [132] . In follow-up to stage 3 trials, other studies have asked whether antigen therapy can delay or prevent progression in stage 1 T1DM disease. No effect has been demonstrated with either nasal [133] or parenteral insulin in stage 1 T1DM [134] . Although a post hoc analysis of data from the DPT-1 trial suggested a benefit from oral insulin 7.5 mg daily in individuals with the highest insulin antibody titers [19, 135, 136] , a fully powered TrialNet study showed no benefit in the primary cohort of more than 300 individuals. However, interestingly, an independently randomized cohort of 55 antibody-positive individuals treated with oral insulin 7.5 mg/day had a 31-month delay in diagnosis of stage 3 T1DM compared with placebo-treated individuals. At enrollment, individuals in this cohort had lower first-phase insulin responses but normal glucose tolerance, perhaps indicating a more active disease state [137] . While the TrialNet study tested a low dose (7.5 mg daily) of oral insulin in stage 1 disease, the GPPAD (Global Platform for the Prevention of Autoimmune Diabetes), a European trial consortium, will test a higher dose of 67.5 mg daily in genetically at-risk children without islet autoimmunity. In POiNT (Primary Oral Insulin Trial), genetically at-risk infants will be identified via either cord blood or newborn screening and then randomized to either placebo treatment or daily oral insulin 67.5 mg/day. The higher 67.5-mg dose of oral insulin was supported by the mechanistic Pre-POINT study, in which children aged 2-7 years with a family history of T1DM, high-risk HLA genotypes, and no islet autoimmunity received either placebo or varying doses of oral insulin. Although Pre-POINT was a small pilot study, results suggested that children who received the highest dose of oral insulin, 67.5 mg/day, had the most salutary immune responses, including regulatory T-cell proliferation in response to insulin [138] . Pre-POINT Early [139] is looking for a similar immune response in a younger cohort, aged 6 months-2 years. Similarly, a TrialNet study called "Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus" tested the effects of both variable oral insulin dosage and dosing schedule on immune responses [140] . In this open-label study, participants aged 3-45 years were treated with either 67.5 mg/day or 500 mg every other week for 6 months.
Selected Current Studies Testing Therapies to Delay Progression to Stage 3 T1DM
Multiple studies to test immunotherapies in either stage 1 or stage 2 T1DM are ongoing, all with the goal of delaying progression to stage 3 T1DM. Some of these studies are highlighted in Table 1 .
What is the Future of T1DM Research?
One can envision a future with multiple therapeutic options to prevent islet autoimmunity and to treat T1DM in all its stages. We will have a greater ability to personalize treatment and to measure response to treatment using diseasespecific biomarkers. However, multiple steps are required between our current understanding of the natural history of T1DM and the clinical use of disease-modifying therapies. Despite its challenges, T1DM research must remain a priority for funding agencies, scientists, clinicians, and patients. While a full discussion of the challenges to T1DM research is outside the scope of this review, we highlight some barriers in the next section.
When does T1DM begin? Understanding the New Disease Model
As evidenced by the new T1DM staging model, established islet autoimmunity (stage 1 or 2 T1DM) inevitably leads to clinical (stage 3) T1DM; therefore, islet autoimmunity should be considered a disease and not a risk for a disease. This understanding might lead to a greater urgency for populationwide screening for islet autoimmunity, funding for T1DM research, and participation in studies. Immunotherapy should be incorporated into endocrinology training so that providers who treat people with islet autoimmunity will be familiar and comfortable with this option as future treatments become available. As reviewed earlier, family members of people with T1DM should be counseled about antibody screening through TrialNet, which currently is the primary means of identifying those with islet autoimmunity in the USA.
Trials
Are Expensive and Slow: What Might Help?
Study Children
The current pathway toward regulatory approval of immunotherapy in T1DM is to first demonstrate safety and efficacy in adults before testing the therapy in children. As with every new therapy, but particularly for children, safety and equipoise are foremost. However, as reviewed earlier, children with T1DM serve to benefit most from potential beta-cell-preserving therapy. Furthermore, the positive results in many T1DM newonset trials are driven by the efficacy in children. This was seen in both the rituximab and the abatacept new-onset trials, shown in Fig. 5 , where the positive result in each study was driven by the response in children aged < 18 years. It is likely that study endpoints could be reached faster and with fewer participants if more children were enrolled. This was one of the conclusions of a panel that met recently to discuss challenges associated with trial design for different age groups [31] .
Use Intermediate Endpoints
With the understanding that established islet autoimmunity is a disease equivalent to T1DM, the development of islet 
Single-Arm Studies
The natural history of T1DM is well described after clinical diagnosis (stage 3), with a predictable age-based fall in C-peptide [9] . Given the robust natural history data, it may not be necessary to include a placebo group in all stage 3 intervention studies. Multiple barriers to clinical trial participation exist, but a single-arm study design may eliminate a barrier for patients who are less likely to enroll if they are not guaranteed treatment with active drug.
Personalize Therapy
In both clinical practice and in clinical trials, it is understood that only a subset of individuals will have a therapeutic response to any given treatment. In a T1DM new-onset study, this suggests a portion of treated participants will maintain C-peptide, whereas the remainder of treated individuals will have a clinical course similar to those receiving placebo, with the expected decline in C-peptide after diagnosis. The so-called responders are identified retrospectively, based on their clinical outcome, without a prior understanding of how they may differ physiologically from nonresponders. In fact, there are likely "endotypes" or T1DM disease subtypes that might be defined by a specific physiologic mechanism. Ongoing and future efforts will describe the physiologic mechanisms underlying endotypes and identify biomarkers to predict and measure response to therapy. With this individualized approach, therapies more likely to be effective for an endotype will be selected and ineffective therapies discarded sooner. Importantly, whether in a clinical trial or clinical practice, an individualized approach would produce greater benefits, fewer risks, and lower costs.
Conclusions
Nearly 100 years after the first clinical use of insulin for T1DM, the management of hyperglycemia and its complications remains the primary focus of T1DM treatment.
Although dramatic improvements have been made in diabetes management tools, including more physiologic insulins, better insulin delivery methods, and real-time glucose monitoring systems, a majority of people with T1DM do not meet the recommended therapeutic targets, and T1DM and its complications remain a significant burden to individuals, families, and society. We now understand that T1DM has a long and measurable preclinical period (stage 1 T1DM) that progresses inevitably to clinical or stage 3 T1DM. Ample evidence also exists that the preservation of any remaining endogenous insulin secretion is clinically important; hence beta-cell-sparing therapies at any stage of T1DM are potentially beneficial. However, although several therapies have proven effective in short-term C-peptide preservation, no treatment has durably interrupted the autoimmune destruction of beta cells. As a result, T1DM is not treated until it becomes clinically apparent, in contrast to the management of other autoimmune conditions. Although continued improvements in hyperglycemia management are welcome and inevitable, the future may see a shift toward treatments that truly modify the disease, whether with immunotherapies to disrupt the progression of islet autoimmunity, therapies to support the beta cell, or therapies to replace beta cells. Chronic or combination therapies to durably preserve insulin secretion might be needed, analogous to the treatment of other chronic autoimmune conditions such as rheumatoid arthritis. Importantly, treatment will become more personalized, to reflect the heterogeneity of T1DM in all of its stages.
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